Skip to Main Content

An inhaled antibiotic from Insmed (INSM) successfully treated patients with a rare lung disease caused by a bacterial infection, according to results from a phase 3 clinical trial reported Tuesday.

Based on the findings from the phase 3 study, Insmed said it plans to seek accelerated approval from the FDA for the inhaled antibiotic, known as ALIS, as a new treatment for adults with nontuberculous mycobacterial (NTM) lung disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.